Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Key Highlights
- ➤Outlook Therapeutics appoints Greg DiPasquale Chief Commercial Officer
- ➤U.S. LYTENAVA availability targeted before end of 2026
- ➤LYTENAVA is the only FDA-approved ophthalmic bevacizumab formulation in the U.S.
- ➤Outlook commenced LYTENAVA commercial launch in Germany, Austria, and the UK
Expert Statements
Bob Jahr, Chief Executive Officer of Outlook Therapeutics
“Greg has spent his career putting experienced teams in front of retina specialists at the moments that matter most, and he has already built the foundation of our commercial organization. As we move from approval to launch, his leadership and his relationships across the retina community will be central to bringing LYTENAVA to physicians and patients”
Greg DiPasquale, Chief Commercial Officer of Outlook Therapeutics
“Several years ago, while working with higher-priced branded agents, I saw the opportunity to bring an FDA-approved bevacizumab option to patients, providers and payers”
Greg DiPasquale, Chief Commercial Officer of Outlook Therapeutics
“I have been impressed by this team's grit and perseverance in bringing LYTENAVA to approval, and I wanted to be part of making an immediate impact. In my career, I've seen companies that watch it happen, let it happen, or make it happen. Outlook Therapeutics is going to make it happen.”
ISELIN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced Greg DiPasquale as Chief Commercial Officer. Mr. DiPasquale, who joined Outlook in December 2025 as Head of Commercial for LYTENAVA™, will lead all commercial functions as the Company prepares to make LYTENAVA, the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), available to eligible patients in the United States before the end of 2026.
Mr. DiPasquale brings more than 30 years of commercial leadership experience, including nearly two decades in eye care and multiple product launches in retina. LYTENAVA will be the fifth retina launch of his career, following BEOVU(®) (brolucizumab) at Novartis, the EYLEA(®) prefilled syringe and EYLEA(®) HD at Regeneron, and the TRIESENCE(®) relaunch at Harrow.
Get started
Create a free account to read the full story.